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Abstract
Parkinson’s disease (PD) is an α-synucleinopathy characterized by the progressive loss of speciﬁc neuronal populations.
Here, we develop a novel approach to transvascularly deliver proteins of complex quaternary structures, including
α-synuclein preformed ﬁbrils (pff). We show that a single systemic administration of α-synuclein pff triggers pathological
transformation of endogenous α-synuclein in non-transgenic rats, which leads to neurodegeneration in discrete brain regions.
Speciﬁcally, pff-exposed animals displayed a progressive deterioration in gastrointestinal and olfactory functions, which
corresponded with the presence of cellular pathology in the central and enteric nervous systems. The α-synuclein pathology
generated was both time dependent and region speciﬁc. Interestingly, the most signiﬁcant neuropathological changes were
observed in those brain regions affected in the early stages of PD. Our data therefore demonstrate for the ﬁrst time that a
single, transvascular administration of α-synuclein pff can lead to selective regional neuropathology resembling the premotor
stage of idiopathic PD. Furthermore, this novel delivery approach could also be used to deliver a range of other pathogenic,
as well as therapeutic, protein cargos transvascularly to the brain.
Introduction
Parkinson’s disease (PD) is a progressive neurological
disorder deﬁned by the loss of nigrostriatal dopaminergic
neurons and formation of α-synuclein-positive Lewy bodies
(LB) [1]. It is well established that neurodegeneration and
LB pathology affects only a subset of vulnerable cells in
PD. Recent evidence, however, suggests that pathogenic
α-synuclein can propagate between cells and seed pathol-
ogy in a prion-like manner [2, 3]. The question therefore
arises as to why such a spread only generates pathology in
certain neuron populations. Indeed, while neuropathological
studies suggest that there is a stereotypic, spatiotemporal
pattern of LB deposition in post-mortem PD brains [4, 5],
studies using a direct intracerebral injection of α-synuclein
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preformed ﬁbrils (pffs) to transform endogenous
α-synuclein into pathological species are dependent on the
site of injection [6–9]. This approach therefore does not
capture the pathology of PD nor does it reﬂect the experi-
mental evidence suggesting that α-synuclein pathology can
spread from the periphery, via the enteric (ENS), to the
central nervous system (CNS) [10].
Misfolded α-synuclein has been shown to cross the
blood–brain barrier following repeated systemic adminis-
tration, possibly through downregulating endothelial tight-
junction proteins, but at a level that does not generate
α-synuclein pathology or neurodegeneration [11, 12]. We
therefore sought to optimize the efﬁciency of this trans-
vascular protein transduction by taking advantage of a
modiﬁed rabies virus glycoprotein (RVG9R), which has
previously been used to mediate transvascular RNA deliv-
ery to the brain [13, 14]. Negatively charged nucleotides
can be electrostatically complexed with a cationic nona-
arginine sequence, while the RVG ligand itself interacts
with a neural-speciﬁc acetylcholine receptor to induce a
transient membrane inversion and enable translocation of
the RNA cargo into the cytoplasm [15]. By interacting with
anionic amino acids on the surface of proteins, we hypo-
thesized that RVG9R could also be used to enable efﬁcient
protein transduction into the CNS following peripheral
administration, without it affecting the physiological activ-
ities of the cargo protein.
Using this approach, we demonstrate for the ﬁrst time
that systemic delivery of pathological α-synuclein pffs
using this method can lead to selective pathology, neuro-
degeneration, and functional deﬁcits in the rat CNS and
ENS. Critically, this occurs in a pattern that strikingly
mirrors that reported in early-stage, idiopathic PD patients.
This model therefore recapitulates some key features of
early-stage PD, and so has signiﬁcant potential for pre-
clinical testing of putative disease-modifying agents, when
such agents are thought to have their maximal chance of
therapeutic beneﬁt. Finally, the strategy we used for trans-
vascular delivery of α-synuclein could also be leveraged to
deliver other pathogenic and/or therapeutic proteins to
the CNS.
Materials and methods
Peptide/protein complex formation
To prepare the complex for delivery, peptides and protein
cargos were mixed in PBS in a glass vial (Supelco) and left
on an orbital shaker (Stuart SSM1, 60 rpm), for 30 min at
room temperature before use. The optimal (peptide:cargo
protein) molar ratio for application was empirically deter-
mined to be 10:1 for monomeric proteins. The molecular
weights for the heterodimeric chondroitinase ABC
(ChABC) and misfolded α-synuclein pff were assumed to
be 120 and 14.5 kDa, respectively, and the peptide/protein
complex was mixed at a 10:1 molar ratio.
Animal procedures
Female Sprague-Dawley (SD) rats, weighing around 200 g
at the time of injection, were housed with unrestricted
access to food and water unless otherwise stated. Animals
were housed in groups of four on a 12 hours light/dark
cycle. For intravenous delivery, a total volume of 300 μl of
the peptide/protein complex, containing 100 μg of the cargo
proteins or 3 U ChABC per animal, was administered via
the lateral tail vein.
A detailed “Material and methods” section can be found
in the Supplementary information.
Results
The RVG9R system mediates efﬁcient protein
transduction
To ascertain if the RVG9R system could mediate protein
transduction in vitro, monomeric human α-synuclein or the
green ﬂuorescent protein (GFP) were added in culture alone
or mixed with RVG9R at 1:10 molar ratio. Overnight
incubation of RVG9R:α-synuclein or RVG9R:GFP with
primary rat or human foetal cortical neurons, respectively,
induced cellular update of the cargo proteins (Supplemen-
tary Fig. 1a). Adult SD rats were then intravenously
administered with either RVG9R:α-synuclein, RVG9R:
GFP, or appropriate RVG9R or cargo controls and, after
24 hours, distinctive axonal human-speciﬁc α-synuclein and
somatic GFP stainings were detectable in various CNS
regions (Supplementary Fig. 1b). To assess the biodis-
tribution of RVG9R-mediated cargo delivery, animals were
given a single intravenous RVG9R:GFP administration and,
after 24 hours, GFP expression was detectable in the CNS
only when complexed with RVG9R (Supplementary
Fig. 1c). The presence of GFP in the peripheral organs of
RVG9R:GFP injected animals could be attributed to the
rabies virus-mediated anterograde trans-synaptic from the
CNS to the peripheral nerve terminals [16], although further
investigation is required to validate whether RVG9R
behaves in a similar fashion as the intact virus.
We next assessed whether the RVG9R system can
transvascularly deliver biologically active proteins, such as
the heterodimeric ChABC enzyme. The formation of
chondroitin sulfate proteoglycans-enriched perineuronal
nets (PNNs), which are abundantly expressed in the sen-
sorimotor cortex, impedes CNS plasticity, and this can be
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modulated by enzymatic digestion of chondroitin sulfate
chains using ChABC [17]. A single peripheral injection of
RVG9R:ChABC treatment progressively reduced Wisteria
ﬂoribunda agglutinin (WFA)-positive PNNs. Consistently
the expression of unsulfated C-0-S stubs, resulting from
ChABC digestion, was also elevated, although the level of
extracellular cartilage link protein 1 remained unaffected
(Supplementary Fig. 1d, e). This suggested that RVG9R-
delivered ChABC removed chondroitin sulfates without
affecting PNN structure.
RVG9R reversibly complexes with the C-terminus of
α-synuclein
To further understand how RVG9R complexes with pro-
teins, we ﬁrst studied the interaction between RVG9R and
α-synuclein using analytical ultracentrifugation (AUC).
Recombinant human α-synuclein was observed to be
monomeric but, in the presence of RVG9R, a shift of the
sedimentation coefﬁcient was observed, indicative of com-
plex formation (Fig. 1a, b). The interaction was studied in
detail by NMR spectroscopy using 15N-labelled α-synu-
clein, for which chemical-shift assignments were available
[18]. RVG9R was titrated into 15N-labelled α-synuclein and
the chemical-shift changes monitored by 15N heteronuclear
single quantum coherence (HSQC) spectroscopy, until
saturation was achieved (Fig. 1c). By far the most sig-
niﬁcant chemical-shift changes were observed for residues
106–140 at the C-terminus of α-synuclein, which is both
anionic and disordered (Fig. 1d). The shift changes for the
peaks showing the largest changes were ﬁtted to a one-site
model to calculate afﬁnity (Fig. 1e, f). Equilibrium was
achieved within 2 min of the addition of RVG9R for each
titration point. An average dissociation constant (Kd) of 80
± 4 µM for RVG9R:α-synuclein was calculated from the
ﬁtted Kd for residues 120–140 at the C-terminus, leading to
a lower limit of koff > 0.004 s
−1, corresponding to a dis-
sociative half-life (ln2/koff) of <170 s (Fig. 1f). As koff is
independent of concentration, this would be expected to
hold true in vivo.
A single intravenous administration of RVG9R:α-
synuclein pff generates GI and olfactory deﬁcits
It was recently shown that full-length human α-synuclein
pffs have a highly ordered core with unstructured tails [19].
We therefore hypothesized that this C-terminus region
could be accessible to RVG9R complexing and sought to
investigate whether RVG9R-mediated delivery of wild-type
human pff (Supplementary Fig. 2a) can induce α-synuclein
pathology when delivered non-selectively to the nervous
system. Rats were given a single intravenous administration
of either RVG9R:pff, pff alone, or PBS, and followed
behaviourally over a 6-month period. Animals receiving
RVG9R alone were not included as our previous work has
shown that repeated administration of the RVG9R control
did not generate any phenotypes [14]. Over the assessment
period, there were no signiﬁcant group differences in their
locomotor function, motor coordination, and affective
behaviour (Supplementary Fig. 3). There were also no
signiﬁcant group differences in body weight gain or in
faecal proﬁles over the 6-month period. In contrast, solid GI
transit was signiﬁcantly prolonged at 6 months post injec-
tion, speciﬁcally in the RVG9R:pff cohort, suggestive of
subtle GI dysfunction (Fig. 2a). Post-mortem analysis in
these animals revealed phosphorylated α-synuclein inclu-
sions and PK-resistant aggregates in the myenteric plexus,
but not in the submucosal plexus, of the duodenum (Fig. 2b,
Supplementary Fig. 2b). Whilst this was not accompanied
by overt cell loss or changes in total α-synuclein expression
in the duodenum (which exists in dimeric forms [20]), there
was a signiﬁcant increase in glial ﬁbrillary acidic protein
(GFAP) expression in the LMMP, as well as an elevation in
GFAP+ reactive astrocytes around the myenteric plexus
(Supplementary Fig. 2c, d).
Together with GI dysfunction, hyposmia is another
clinical feature of premotor PD. We therefore assessed the
ability of the RVG9R:pff exposed animals to use olfactory
cues for foraging after overnight fasting. In the buried food
test, the RVG9R:pff animals displayed an increasing
retrieval latency over time (Fig. 2c). Similarly, odour-cross
habituation was disrupted in these animals at 6 months post
injection, with a signiﬁcant group effect on the dis-
crimination index (Fig. 2d, e). Post-mortem histopatholo-
gical analysis of the olfactory bulb (OB) revealed
substantial phosphorylation of α-synuclein in the mitral and
granule, but not in the glomerular cell layer, in RVG9R:pff
animals (Fig. 2f). Using the novel pentameric thiophene
derivative (pFTAA) that speciﬁcally recognizes oligomeric
and ﬁbrillar protein species [21], we observed no evidence
of abnormal protein folding in these regions (Supplemen-
tary Fig. 2e). There was however a signiﬁcant elevation in
the number of dopaminergic cells residing locally in the
periglomerular area (Fig. 2f, g), although the level of tyr-
osine hydroxylase (TH) expression and the concentration of
dopamine in the whole OB remained unchanged (Supple-
mentary Fig. 2f–h).
Structural imaging changes on MRI and their
functional correlates
We next examined if there were any macroscale changes in
rat brain volume following RVG9R:pff exposure and if so,
how these related to the subtle behavioural phenotype of
these animals. Comparing the relative volumes of the
summary regions of interest (ROIs) for total grey and white
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matter and the individual rat brain ROIs (n= 79), there
were no signiﬁcant treatment effects after multiple com-
parison adjustment (Fig. 3a). The relative volumes of the
olfactory system were also not affected, despite the presence
of olfactory deﬁcits (Fig. 3a). The relative volumes of two
individual atlas ROIs in the RVG9R:pff rats, the medial
cerebellar peduncle (MCP) and the pyramidal decussation
(PDec), were increased (+5) and decreased (−14), respec-
tively (Fig. 3a). Effect sizes (Cohen’s d) for each region
were +1.3 and −1.3, respectively. Whole-brain, voxel-wise
TBM analysis conﬁrmed these data, with no signiﬁcant
volumetric changes between treatment groups after strin-
gent correction for multiple comparisons (family-wise error
rate, p < 0.05). There were however clusters of voxels with
both apparent changes in volume diffusely in the neocortex,
brain stem, and cerebellum, at an exploratory threshold of p
< 0.05 (uncorrected, Fig. 3b).
We next explored our MRI dataset for correlations
between relative brain ROI volumes in the RVG9R:pff
treated animals with their performance in the buried food
test. Since this is an exploratory analysis we did not correct
the resulting p values for multiple comparisons. This ana-
lysis suggested that two ROIs, the neocortex and anterior
commissure, were negatively correlated with olfactory
impairment, such that smaller relative volumes of these
structures were associated with longer retrieval latency
(Fig. 3c). A further 2/80 ROIs, the pontine nuclei and the
bed nucleus of the stria terminalis (BNST), were positively
correlated with performance on the buried food test
(Fig. 3c). There were no such correlations with any of these
regions in the control group.
RVG9R:pff treatment induces neurodegeneration in
the midbrain and brain stem
We next sought to deﬁne whether there was any relevant
CNS histopathology in brain regions reported to show
neuropathology in early-stage PD [4, 5], as well as relevant
sites affected at trend level in the MRI data. There were
signiﬁcant reductions of TH+ and vesicular monoamine
Fig. 1 RVG9R interacts with the C-terminus of α-synuclein. a AUC
sedimentation velocity data for α-synuclein alone, and in the presence
RVG9R (both 30 μM). b α-Synuclein was monomeric with an so20,w
value of 1.2 S, assuming a uniform frictional ratio of Fk,w ~ 1.9. The
value of so20,w increased to 1.4 S in the presence of RVG9R, indicative
of complex formation. Free RVG9R was observed close to s= 0. The
ﬁnal root-mean-square deviation was 0.04 in each case. c HSQC of
15N α-synuclein with a saturating level of RVG9R (30:1 molar ratio),
and d chemical-shift difference vs residue number. e HSQC of 15N α-
synuclein with increasing concentrations of RVG9R. f Representative
data showing Kd extraction from Δδ of Glu130 using a 1:1
binding model
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transporter-positive (VMAT2+) dopaminergic neurons in
the SNc in RVG9R:pff injected rats, at 6 months post
injection (Fig. 4a, b, Supplementary Fig. 4a, b). These
pathologies were likely to have resulted from endogenous
rodent α-synuclein aggregation, as no human α-synuclein
was detected in the host brain at 6 months after the one-off
intravenous administration (Supplementary Fig. 4c),
consistent with the injected pff seeding host pathology.
There was also a progressive decline in noradrenergic cell
density in the locus ceruleus (LC), cholinergic neurode-
generation in the dorsal motor nucleus of the vagus nerve
(DMN-X), as well as in the hypoglossal nerve (DMN-XII)
(Fig. 4d–f). These inclusion bodies in the DMN-X were PK-
resistant, LB-like, amorphous precipitates that were reactive
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to thioﬂavin-S (Supplementary Fig. 5a). Such inclusions
were also ubiquitylated and phosphorylated at the serine-
129 residue of α-synuclein (Supplementary Fig. 5b).
RVG9R:pff treatment generates site-speciﬁc and
time-dependent α-synucleinopathy
These data provided justiﬁcation for further analysis, which
revealed a differential pattern of α-synuclein pathology
across different brain regions. For instance, LB-like, phos-
phorylated α-synuclein inclusions were observed in the LC
and DMN-X, with pFTAA-positive oligomers found sur-
rounding the inclusion bodies (Fig. 5a). The presence of
both voluminous and threadlike Lewy pathologies, similar
to those described in the dorsal medulla of idiopathic PD
patients [22], could be detected in the DMN-X at 6 months
after RVG9R:pff injection (Fig. 5a). The presence of α-
synuclein pathology could be observed in other brain
regions that have previously been implicated in early-stage
PD, such as the anterior olfactory nucleus and the SNc. The
selective nature of the pathology observed was also evi-
denced by the absence of pathology at other sites, such as
the thalamus and hippocampus, at 6 months after RVG9R:
pff injection (Fig. 5a).
Finally, the extent of α-synuclein aggregation was
assessed using western immunoblotting. Triton-, SDS-, and
urea-soluble α-synuclein were sequentially extracted from
different regions of the CNS and ENS. At 6 months after
RVG9R:pff injection, Triton-soluble fractions displayed
both total and phosphorylated, monomeric α-synuclein in
all brain regions and dimeric α-synuclein in the duodenum
(Fig. 5b). The presence of high molecular weight (HMW)
α-synuclein in the SDS-soluble fraction, with the absence of
α-synuclein in the cerebellum, OB, and in the duodenal
mucosa in the urea-soluble fraction, indicates that there is a
region-speciﬁc susceptibility to intravascularly delivered
pathogenic pff (Fig. 5b). Using the cortex as an example,
aggregation of α-synuclein in RVG9R:pff rats was also
found to be a time-dependent process, as both the size and
intensity of HMW α-synuclein was progressively increased
in the urea-soluble fraction in animals receiving RVG9R:pff
(Fig. 5c, d). The presence of phosphorylated α-synuclein in
the Triton- and SDS-soluble fractions of PBS-injected ani-
mals was likely associated with the membrane ﬁxation
process used to enhance the sensitivity of detecting HMW
α-synuclein [23].
Discussion
There is increasing evidence demonstrating that misfolded
α-synuclein can spread from one cell to another, possibly
through direct synaptic transfer, or via exosomes, tunnelling
nanotubes, and LAG3-dependent endocytosis [24–27]. The
relevance of such spread in the pathogenesis of idiopathic
PD however remains debated [28]. In this study, we have
developed a novel method to systemically deliver patho-
genic α-synuclein pff, and demonstrated that a single
intravascular injection using this approach can induce a
region-selective and time-dependent neuronal pathology
resembling that is seen in premotor, idiopathic PD. This
strategy therefore provides a potential model system to
study the earliest stages of disease pathogenesis in PD. This
not only will improve our understanding of the mechanism
and functional relevance of α-synuclein pathogenic spread,
but will also be beneﬁcial for the evaluation of novel
disease-modifying therapeutics. Moreover, therapeutic pro-
teins could also be delivered using this same carrier system,
as we have described here using RVG9R:ChABC
and previously with RVG9R:p137 in neurotoxic models of
PD [14].
While there are many symptomatic treatments for the
dopaminergic aspects of PD, no disease-modifying thera-
pies have yet been successfully translated to the clinic. This
is in part due to the lack of animal models recapitulating the
earliest stages of this disease. Most neurotoxin-based
models are acute in nature without generating
α-synucleinopathy. Similarly, transgenic models only
represent a small proportion of the familial PD cases, and
Fig. 2 Transvascular RVG9R:pff delivery generates GI and olfactory
impairments. a No group differences were observed in body weight
and faecal proﬁles over time, although there was a treatment effect in
GI transit (F2,55= 4.559, p= 0.015), reaching statistical signiﬁcance at
6 months after a single intravenous RVG9R:pff injection (p= 0.021 vs
pff alone, p= 0.028 vs PBS). b Abnormally phosphorylated (DAB-
peroxidase, green arrows) and PK-resistant α-synuclein inclusions
(red) were detected in the duodenal myenteric plexus (peripherin,
green). c There was a signiﬁcant treatment effect in the latency to
retrieve food at 6 months post injection (F2,54= 4.483, p= 0.016),
post hoc analysis vs pff alone (p= 0.002) and PBS (p= 0.003) groups.
d There was a trend for the RVG9R:pff treated rats to be less capable
at discriminating the new odour presentation (A3-B1) at 6 months post
injection, although this failed to reach signiﬁcance after post hoc
adjustment. e There was a signiﬁcant reduction on the discrimination
index in the RVG9R:pff rats at 6 months post injection (F4,43= 2.710,
p= 0.042), post hoc analysis vs PBS at 6 months post injection (p=
0.041) and RVG9R:pff at 2 months post injection (p= 0.022).
f Extensive α-synuclein phosphorylation (Ser129, red) was found in
the mitral and granule cell layers, with more TH+ neurons (green) also
being observed in the periglomerular region in the RVG9R:pff rats.
g There was a signiﬁcant increase in the TH cell counts per glomerulus
in the RVG9R:pff rats at 6 months post injection (F2,33= 39.843, p <
0.001), post hoc analysis vs pff only (p < 0.001) and PBS (p < 0.001)
groups. *p < 0.05, **p < 0.01, ***p < 0.001 compared with PBS group
at the same time point. Data were analyzed using multivariate
ANOVA or repeated measure ANOVA in d. n= 6–8 per group at 2/
4 months post injection, n= 9–12 at 6 months post injection. Three
glomeruli were randomly selected for analysis from each animal and
averaged in g. Nuclei were counterstained with Hoechst (blue). Scale
bars, 30 µm
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Fig. 3 RVG9R:pff treatment induces subtle neuroanatomical changes
on MRI at 6 months post injection. a Data shown are the relative
volume differences by region, derived from ABS of MR images. No
changes survived adjustment for multiple comparisons (5% false dis-
covery rate, FDR). A trend (F1,22= 4.188, p= 0.053) for global grey
matter atrophy was observed in the RVG9R:pff treated rats. Increased
relative volume of the MCP (+5%, F1,22= 8.693, p= 0.007, uncor-
rected q= 0.33) and a decreased relative volume of PDec (−14%,
F1,22= 8.470, p= 0.008, uncorrected q= 0.33), were also observed in
RVG9R:pff rats. b At an exploratory threshold (p < 0.05 uncorrected),
RVG9R:pff exposure induced subtle effects on local volume and
revealed previously unappreciated clusters of voxels with volumetric
changes in the brain stem and cerebellum. c Linear regression revealed
signiﬁcant correlations between the relative volumes of four brain
regions (r2= 0.50 for neocortex, r2= 0.39 for anterior commissure,
r2= 0.43 for pontine nuclei, and r2= 0.36 for BNST) and retrieval
latency in the buried food test in RVG9R:pff treated rats. Associated
p values (uncorrected) are shown. *p < 0.05, **p < 0.01. Data were
analyzed using t-tests for each atlas ROI and then corrected using
FDR. Data shown in b are the results of statistical testing for differ-
ences in the log scaled Jacobean determinant between RVG9R:pff and
PBS-injected rats, at an exploratory threshold of p < 0.05 uncorrected
for multiple comparisons. n= 12 per group
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even in these models, α-synuclein pathology is often not
sufﬁcient to induce neurodegeneration at sites relevant to
PD [29]. Animal models generated by direct pff inoculation
faithfully reproduce many of the pathological features that
are seen in the post-mortem brains from idiopathic PD cases
[6–9]. Nevertheless, direct intracerebral pff injection never
induces pathology outside the brain, at odds with the clin-
ical picture of idiopathic PD in which α-synuclein pathol-
ogy is abundant in the ENS and may precede that found
centrally [30]. Although a recent study has demonstrated
that an enteric inoculation of pff generates pathological
features in the GI system that propagates into the CNS [31],
such ﬁndings have not been universally reported [32–34].
Thus, whether ENS abnormalities precede and relate to the
onset of motor problems in idiopathic PD is still a matter of
debate [35]. Nevertheless, a transvascular delivery of pffs
that critically generates pathology only in selective, PD-
related CNS and ENS sites, renders our RVG9R:pff model
clinically relevant, given its ability to recapitulate the
α-synuclein pathology seen in many patients with early-
stage PD.
The molecular mechanism causing such differential
susceptibility remains elusive. As the propagation of
α-synucleinopathy is dependent on the level of α-synuclein
of the recipient cells [6], it has been hypothesized that
selective neuronal vulnerability may relate to the differential
expressions of endogenous α-synuclein. Indeed, glutama-
tergic neurons in the hippocampus express higher endo-
genous α-synuclein levels and are more susceptible to PFF
toxicity than GABAergic neurons [36]. Similarly, a subset
Fig. 4 A single intravenous injection of RVG9R:pff induces pro-
gressive CNS pathology in non-transgenic rats. a Representative pic-
tures of the TH+ dopaminergic neurons in the midbrain of adult rats. b
There was a signiﬁcant treatment effect on TH+ cell counts in the SNc
(F2,71= 16.242, p < 0.001), post hoc analysis revealed a signiﬁcant
dopaminergic neurodegeneration vs pff alone (p= 0.01) at 4 months
post injection, and vs pff alone (p < 0.001) and PBS (p < 0.001) groups
at 6 months post injection. c Representative pictures of the DBH+
noradrenergic neurons in the LC. d There was a signiﬁcant treatment
effect on DBH+ cell numbers per mm3 in the LC (F2,45= 4.708, p=
0.014), post hoc analysis revealed a signiﬁcant noradrenergic neuro-
degeneration vs pff alone (p= 0.002) and PBS (p= 0.012) groups at
6 months post lesion. e Representative pictures of the ChAT+ choli-
nergic neurons in the DMN-X (green arrows) and DMN-XII. f There
was a signiﬁcant treatment effect over time on ChAT+ cell counts in
the DMN-X (F4,53= 2.799, p= 0.035), as well as in the DMN-XII
(F4,53= 3.005, p= 0.033), post hoc analysis revealed a signiﬁcant
cholinergic neurodegeneration in the DMN-X vs pff alone (p < 0.001)
and PBS (p < 0.001) groups, as well as in the DMN-XII vs pff alone (p
< 0.01) and PBS (p < 0.01) groups, at 6 months post lesion. *p < 0.05,
**p < 0.01, ***p < 0.001 compared with pff only group at the same
time point. Data were analyzed using multivariate ANOVA, n= 6–12
per group at 2 and 4 months post injection, n= 8–12 at 6 months post
injection. Scale bars, 500 µm for a and e, and 100 µm for c
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of Math2+ glutamatergic neurons in the hippocampus are
more susceptible than Prox1-containing glutamatergic
neurons in the dentate gyrus, which is again related to the
differential expression of endogenous α-synuclein [37].
However, this cannot be the whole story, as many brain
areas have similar levels of endogenous α-synuclein yet
exhibit selective PD pathology [38].
There are some limitations despite the obvious utility of
the RVG9R:pff model. The modest level of nigral dopa-
minergic cell loss (15–20%) at 6 months post injection was
inadequate to generate motor impairments. This likely also
explains our MRI ﬁndings of no clear brain atrophy fol-
lowing adjustment for multiple comparisons. There were,
however, some regional volumetric changes, which corre-
lated with olfactory dysfunction, albeit at an exploratory
threshold. For example, the negative correlation between
cortical volume and olfactory performance in the RVG9R:
pff-exposed rats is in good agreement with similar rela-
tionships in non-demented older adults with olfactory
impairment [39, 40] and in PD patients with no co-morbid
dementia [41, 42], although such changes are not found in
all studies [43]. The positive correlations with changes in
the pontine nuclei and BNST are slightly harder to interpret,
since these regions do not have obvious involvement in
olfactory processing. Nevertheless, such changes could be
related to neuropathological changes, such as neuronal
swelling and gliosis in these regions, associated with sys-
temic RVG9R:pff administration. However, it should be
noted that these correlations were exploratory and not cor-
rected for multiple comparisons, and so should be viewed
cautiously. Further studies will be required to conﬁrm these
relationships and elucidate the cellular correlates driving
them. Overall though, our MR imaging endophenotype is
consistent with the general lack of structural brain pathol-
ogy detected by MRI in de novo PD patients [44]. Our data
are also consistent with other reports that have injected pff
directly into the brain, where the neuropathology and rela-
tionship to behavioural dysfunction may become clearer
with longer follow-ups coupled to longitudinal in vivo MR
imaging.
We did however detect a signiﬁcant cholinergic neuro-
degeneration in the DMN-XII at 6 months in the RVG9R:
pff rats. Although the presence of ubiquitin-positive
degenerating neurites in the DMN-XII has been pre-
viously reported in PD patients [45], cholinergic neurode-
generation has not been established in this area. This could
be attributed to the intrinsic biological difference between
rodent and human cholinergic neurons in the DMN-XII,
contributing to their differential susceptibility to
α-synuclein pathology. However, a trend of cholinergic
neurodegeneration (p= 0.073) in the DMN-XII has recently
been reported in patients dying with incidental LB disease,
but intriguingly not in idiopathic PD patients [22]. Promi-
nent α-synuclein pathology could also be observed in the
cortical regions at 6 month after RVG9R:pff injection. It is
possible that transvascular delivery of α-synuclein may lead
onto cognitive deﬁcits, which deﬁne prodromal PD
dementia [46], although we did not thoroughly explore this
in our study. Furthermore, we used human pff as opposed to
rodent pffs, which may be better to generate pathology, as
homologous seeding is more efﬁcient and pathogenic than
cross-seeding [7].
Another limitation of the current study is that our ana-
lysis in the periphery was restricted to describing the
behavioural and cellular deﬁcits in the GI tract in the
RVG9R:pff animals, and there may be additional patholo-
gical features that we did not examine (e.g. heart) [47, 48].
Similarly, our histological examination of the CNS was
restricted to the brain regions that have been well estab-
lished to have pathology in early PD. This was also driven
by our MRI analysis. Nonetheless, the datasets presented
herein converge to suggest that we have a phenotype at
6 months of age consistent with early-stage PD.
In addition to developing this highly relevant new model
of premotor PD, we have also shown that the RVG9R carrier
is a versatile system for in vivo protein transduction to
complement its previously deﬁned uses in the transvascular
delivery of small interfering RNA [13], non-coding RNA
[14], and liposome-encapsulated nucleotides [49]. As we have
Fig. 5 Site-speciﬁc and time-dependent α-synuclein pathology after a
single systemic injection. a Representative ﬁgures showing the degree
of α-synuclein phosphorylation (Ser129, red) and oligomerization
(pFTAA, green) with confocal microscopy in various brain regions, as
well as the presence of PK-resistant inclusions in bright-ﬁeld micro-
scopy in DMN-X. Lewy neurite-like structures, as well as LB-like
structures with a dense core of phosphorylated α-synuclein surrounded
by pFTAA+ oligomers, was detectable in the SNc and DMN-X. n=
6–12 per group per time point. b Representative blots showing the
development of total (syn42) and phosphorylated (Ser129) α-synuclein
aggregation after sequential protein extraction, comparing between
various regions of the CNS and ENS. At 6 months post injection, total
and phosphorylated α-synuclein was detectable in the urea-soluble
fraction in all brain regions except for the cerebellum (CB) and OB, as
well as in the duodenal LMMP but not in the mucosa. c The aggre-
gation and phosphorylation of α-synuclein in the CTx was also time
dependent in the urea-soluble fraction. d Semi-quantitative analysis on
the level of monomeric and HMW α-synuclein in the urea-soluble
fraction, at 6 months post injection. There was a signiﬁcant interaction
effect between treatment and α-synuclein conformation (F8,58= 5.748,
p < 0.001). Post hoc analysis revealed no signiﬁcant difference in the
expression of Syn42 α-synuclein monomers between 2 and 6 months
post injection, although there was a signiﬁcant increase in HMW total
α-synuclein aggregation between 2 and 4 months post injection. On
the contrary, the expression of Ser129 phosphorylated α-synuclein was
signiﬁcantly elevated between 2 and 4 months post injection, both in
terms of monomeric (p= 0.031), and HMW α-synuclein (p < 0.001).
Abbreviations include cortex (CTx), basal ganglia (BG), midbrain
(Mid), brain stem (BS), and duodenal mucosa (Mus). n= 4 per group
per time point. Nuclei were counterstained with Hoechst (blue). Scale
bars, 30 µm for confocal microscopy and 60 µm for bright-ﬁeld
microscopy
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shown here, cargo complexing was simple and achievable
within 30min, in contrast to alternative approaches that
require laborious procedures and extensive preparations to
create chimeric, CPP-cargo fusion constructs. We have also
ascertained that the same delivery system can be adapted to
deliver a range of protein cargos including GFP, hetero-
dimeric ChABC, as well as α-synuclein ﬁbrils. In principle
the same strategy could also be used to model other neuro-
degenerative proteinopathies [50].
In summary we have developed a new animal model in
which the transvascular delivery of RVG9R:pff mirrors the
earliest pathology and behavioural deﬁcits of premotor PD.
This opens up new ways to study PD pathogenesis and its
treatment, and critically disease-modifying therapies that are
likely to have their greatest impact at the onset of the dis-
ease process.
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